Litcius/Paper detail

Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update

Michael Klompas, Majdi N. Al‐Hasan, Mayar Al Mohajer, Robert C. Colgrove, Shira Doron, Thomas M. File, Natasha N. Pettit, Michael S. Pulia, Sharon Weissman

2025Clinical Infectious Diseases8 citationsDOI

Abstract

The American Thoracic Society recently released updated community-acquired pneumonia (CAP) guidelines. The Infectious Diseases Society of America (IDSA) agreed with 8 of the 10 recommendations in the guidelines but declined to endorse the guidelines because they include recommendations for use of antibiotics in outpatients with comorbidities and inpatients with nonsevere CAP who test positive for respiratory viruses. It is noted in the guidelines that bacterial coinfections are common and that delaying antibiotics may be harmful. IDSA notes, however, that nondiscriminatory use of antibiotics for patients with CAP and positive viral assays confers more risks than benefits. Most patients do not have bacterial coinfections, and briefly withholding antibiotics for patients with nonsevere illness to clarify the diagnosis is safe. In this era of precision medicine, IDSA instead recommends individualized, dynamic decision-making that takes into account each patient´s evolving trajectory, severity of illness and balance of clinical features for and against coinfection.

Topics & Concepts

MedicinePneumoniaIntensive care medicineAntibioticsPosition paperCoronavirus disease 2019 (COVID-19)MEDLINESevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakBacterial pneumoniaCommunity-acquired pneumoniaViral pneumoniaFamily medicinePneumonia and Respiratory InfectionsAntibiotic Use and ResistanceRespiratory viral infections research
Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update | Litcius